People with type 2 diabetes who do not achieve target glycated hemoglobin (HbA1c ≤7.0%) despite glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy may require additional strategies to improve metabolic control. A prospective cohort study published in Advances in Therapy evaluated the effect of adding flash glucose monitoring to ongoing GLP-1RA therapy over 12 months.

The study enrolled 264 people with type 2 diabetes receiving stable GLP-1RA therapy who had not reached the HbA1c target. Participants were assigned to flash glucose monitoring plus GLP-1RA or GLP-1RA alone, matched by age and baseline HbA1c using a nearest-neighbor approach. After 12 months, mean HbA1c decreased by −0.58% (from 8.24% to 7.66%) in the flash monitoring group compared with −0.35% (from 8.32% to 7.97%) in the GLP-1RA-only group (p<0.001). Body weight decreased by −4.03 kg (from 83.97 to 79.95 kg) versus −2.29 kg (from 84.75 to 82.50 kg), respectively (p<0.001).

Total cholesterol and triglycerides decreased significantly, and high-density lipoprotein cholesterol increased in the flash monitoring group, while changes were minimal in controls. Low-density lipoprotein cholesterol decreased within the flash monitoring group, although the between-group difference did not reach statistical significance. Mean time-in-range was 69.6%, with low hypoglycemia exposure and no signal for increased severe events or diabetes-related emergencies.

These findings describe greater improvements in glycemic and selected metabolic parameters over 12 months among individuals using flash glucose monitoring in addition to GLP-1RA therapy.